Product image of Mirabegrón Alter (Mirabegron) supplied by GNH India

Mirabegrón Alter

Active Ingredient:
Mirabegron
Origin:
EU

Mirabegrón Alter (Mirabegron)

Mirabegron, the active ingredient in Mirabegrón Alter, is a β3‑adrenergic receptor agonist presented as an oral formulation for prescription use. It is indicated for the management of overactive bladder symptoms, including urinary urgency, frequency and urge incontinence, in adult patients.

GNH India supplies Mirabegrón Alter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑approved batches to global markets.

Manufacturer / TM Owner

Laboratorios Alter, S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mirabegron is used to treat conditions within the overactive bladder disease family, improving bladder storage function.

  • Overactive bladder: increases bladder capacity and reduces urgency episodes.
  • Urinary urgency: lessens the sudden need to void.
  • Urinary frequency: decreases the number of daytime voids.
  • Urge urinary incontinence: reduces involuntary leakage episodes.

How It Works

  • Mirabegron selectively activates β3‑adrenergic receptors located on detrusor smooth muscle. Activation triggers cyclic AMP accumulation, leading to relaxation of the detrusor muscle during the storage phase of the micturition cycle. This relaxation expands functional bladder capacity, thereby decreasing the frequency of urgency and incontinence episodes in patients with overactive bladder.

Side Effects

Adverse reactions reported with mirabegron can be grouped by frequency.

Common Side Effects

  • Hypertension: mild to moderate increase in blood pressure.
  • Nasopharyngitis: inflammation of the nasal passages and throat.
  • Urinary tract infection: symptoms of dysuria or frequency.
  • Headache: mild to moderate intensity.
  • Constipation: reduced bowel movements.
  • Dry mouth: decreased salivation.

Serious or Rare Side Effects

  • Urinary retention: difficulty emptying the bladder.
  • Severe hypertension: marked elevation of blood pressure requiring medical intervention.
  • Angioedema: swelling of face, lips, or airway.
  • Tachycardia: rapid heart rate.
  • Allergic reactions: rash, pruritus, or anaphylaxis.

Precautions & Warnings

When prescribing mirabegron, clinicians should consider several safety measures.

  • Blood pressure monitoring: check baseline and periodically during therapy.
  • Renal function assessment: evaluate in patients with moderate to severe impairment.
  • Concomitant antihypertensive review: adjust doses if additive blood pressure‑lowering occurs.
  • Elderly caution: start at lower dose and monitor for orthostatic effects.
  • Avoid use in uncontrolled hypertension: contraindicated.
  • Store at ambient temperature: keep in original packaging, protect from moisture.

Avoid Interactions

Mirabegron may affect the plasma levels of other medicines through enzyme modulation.

Major Interactions (Avoid)

  • Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase mirabegron exposure.
  • Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can raise plasma concentrations.
  • Other β3‑adrenergic agonists: additive pharmacologic effects.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance risk of hypotension.
  • Antimuscarinic bladder agents (e.g., oxybutynin): monitor for synergistic urinary effects.
  • NSAIDs: assess renal function when combined with mirabegron.

Frequently Asked Questions

Mirabegrón Alter is prescribed to manage overactive bladder symptoms, including urinary urgency, increased daytime frequency, and urge urinary incontinence. By improving bladder storage capacity, it helps reduce the frequency of sudden urges and accidental leakage in adult patients.

Mirabegron selectively stimulates β3‑adrenergic receptors on detrusor smooth muscle. This activation raises cyclic AMP levels, causing the muscle to relax during the bladder‑filling phase, which expands functional capacity and lessens urgency and incontinence episodes.

The dosage of Mirabegrón Alter is determined by the prescribing clinician based on the patient’s medical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical advice.

Safety data for mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirabegron belongs to a different class (β3‑adrenergic agonist) than antimuscarinic agents, which block muscarinic receptors. Mirabegron often has a lower incidence of dry mouth and constipation, common side effects of antimuscarinics, but may raise blood pressure, requiring monitoring.

Mirabegrón Alter should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid environments.

Mirabegrón Alter is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include significant hypertension, urinary retention, and rare allergic reactions such as angioedema. Patients should report any sudden increase in blood pressure, difficulty urinating, or signs of an allergic response to their healthcare provider promptly.

Mirabegron Alter is contraindicated in patients with uncontrolled hypertension, severe renal impairment, or known hypersensitivity to mirabegron or any excipients. Caution is also advised for individuals taking strong CYP2D6 or CYP3A4 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mirabegron

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT